Skip to content
value.today

Genophen Inc.

Total raised
$14 M
5 rounds on record
Latest round
$5 M
Jun 2017
First round on record
Apr 2011
Today
Private
No later event on record

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genophen Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2017$5 MNo. 5$2 to $10 million

Genophen Inc.: Raise no. 5, Jun 2017

Investors in this round

5 investors had bought by the notice of Jul 12, 2017: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $9 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series C Preferred Stock (""Series C"") and the underlying shares of Common Stock issuable upon conversion of Series C."
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hossein Fakrai-Rad · Executive Officer, Director
  • Jason Pyle · Executive Officer, Director
  • Kazutaka Ohno · Executive Officer
  • Prakish Menon · Executive Officer, Director
  • Mostafa Ronaghi · Director
  • Saeid Akhtari · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jason Pyle, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 12, 2017. Read the notice at the SEC.

equitySEC
May 2015$4 MNo. 4$2 to $10 million

Genophen Inc.: Raise no. 4, May 2015

Investors in this round

20 investors had bought by the notice of Jun 1, 2015: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: "Offering of Series B Preferred Stock (""Series B"") and the underlying shares of Common Stock issuable upon conversion of Series B."
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Hossein Fakhrai-Rad · Executive Officer, Director
  • Kazutaka Ohno · Executive Officer
  • Prakish Menon · Executive Officer, Director
  • Babak Yazdani · Director
  • Mostafa Ronaghi · Director
  • Saeid Akhtari · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hossein Fakhrai-Rad, President. Source: SEC Form D, newest notice filed Jun 1, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$2 MNo. 3$2 to $10 million

Genophen Inc.: Raise no. 3, Oct 2013

Investors in this round

15 investors had bought by the notice of Nov 22, 2013: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Arman Pahlavan · Executive Officer
  • Hossein Fakhrai-Rad · Executive Officer, Director
  • Kazutaka Ohno · Executive Officer
  • Babak Yazdani · Director
  • Farzad Naimi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arman Pahlavan, Secretary. Source: SEC Form D, newest notice filed Nov 22, 2013. Read the notice at the SEC.

equitySEC
May 2012$2 MNo. 2Under $2 million

Genophen Inc.: Raise no. 2, May 2012

Investors in this round

19 investors had bought by the notice of May 17, 2012: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Arman Pahlavan · Executive Officer
  • Hossein Fakhrai-Rad · Executive Officer, Director
  • Babak Yazdani · Director
  • Farzad Naimi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hossein Fakhrai-Rad, President. Source: SEC Form D, newest notice filed May 17, 2012. Read the notice at the SEC.

equitySEC
Apr 2011$1 MNo. 1Under $2 million

Genophen Inc.: Raise no. 1, Apr 2011

Investors in this round

16 investors had bought by the notice of May 3, 2011: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Arman Pahlavan · Executive Officer
  • Hossein Fakhrai-Rad · Executive Officer, Director
  • Babak Yazdani · Director
  • Farzad Naimi · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Arman Pahlavan, Secretary. Source: SEC Form D, newest notice filed May 3, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genophen Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2017).

    SEC Form D · Jul 2017

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jul 2017

That is all the official record says: Genophen Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Genophen Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 20 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genophen Inc.
NameRoleNamed in
Hossein Fakrai-RadExecutive officerJul 2017
Jason PyleExecutive officerJul 2017
Kazutaka OhnoExecutive officerJul 2017
Prakish MenonExecutive officerJul 2017
Hossein Fakhrai-RadExecutive officerJun 2015
Arman PahlavanExecutive officerNov 2013
Hossein Fakrai-RadDirectorJul 2017
Jason PyleDirectorJul 2017
Mostafa RonaghiDirectorJul 2017
Prakish MenonDirectorJul 2017
Saeid AkhtariDirectorJul 2017
Babak YazdaniDirectorJun 2015
Hossein Fakhrai-RadDirectorJun 2015
Farzad NaimiDirectorNov 2013